FDA Drug Label
ELMIRON (pentosan polysulfate sodium) — Prescribing Information
Janssen, 1996
PPS
Heparinoid compound used clinically in non-peptide indications; sometimes tracked in protocol stacks.
Overall check-ins
Trackers & reports
Overview
Heparinoid compound used clinically in non-peptide indications; sometimes tracked in protocol stacks.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 17% · Unfavorable overall 83%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports cluster around 0–25 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Research
FDA Drug Label
Janssen, 1996
PubMed
Bannuru et al., 2020
PubMed
Siddiq et al., 2024
PubMed
Ghosh, 1999
Tools
More ways to learn about Pentosan Polysulfate from observational PeptIQ data.
Compare with
Related peptides
Help
This page summarizes 6 anonymized self-reports from PeptIQ users who track Pentosan Polysulfate, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. Pentosan Polysulfate is listed as FDA Approved / Other Indications. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests Pentosan Polysulfate may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourcePentosan Polysulfate is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Pentosan Polysulfate as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of Pentosan Polysulfate have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on Pentosan Polysulfate, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source